Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

Drugs Inhibiting the KRAS Oncogene Suppress Growth of Pancreatic Tumors in Mouse Xenograft Model

By BiotechDaily International staff writers
Posted on 14 Jun 2013
Drugs that inhibit the activity of the enzyme GSK-3 alpha (glycogen synthase kinase 3 alpha) strongly suppress growth of human pancreatic tumor xenografts in mice as well as down regulate certain oncogenic NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) target genes.

GSK-3 has since been identified as a kinase for over forty different proteins in a variety of different pathways. In mammals, GSK-3 is encoded by two known genes, GSK-3 alpha and GSK-3 beta. GSK-3 has recently been the subject of intense research because it has been implicated in a number of diseases, including type II diabetes, Alzheimer's disease, inflammation, cancer, and bipolar disorder.

Investigators at the University of North Carolina (Chapel Hill, USA) have found that in pancreatic cancer cells GSK-3 alpha is upregulated by mutant KRAS (Kirsten rat sarcoma viral oncogene). The KRAS gene performs an essential function in normal tissue signaling, and its mutation is an essential step in the development of many cancers. A single amino acid substitution is responsible for the activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, and colorectal carcinoma.

In a paper published in the April 1, 2013, online edition of the journal Cancer Discovery, the investigators reported that GSK-3 alpha was required for promoting critical NF-kappaB signaling in pancreatic cancer cells. The transcription factors of the NF-kappaB family are upregulated in many human cancers. NF-kappaB has roles in all stages of carcinogenesis or cancer progression, including protection from cell death, increase of cell proliferation, cell motility and metastasis, tumor inflammation, and angiogenesis. In addition, tumor cells often acquire resistance to anticancer drugs by upregulating NF-kappaB signaling.

Pharmacologic inhibition of GSK-3 suppressed growth of human pancreatic tumor explants in mice, consistent with the loss of expression of oncogenic genes such as c-myc and TERT.

“GSK-3 promotes activity of a protein called NF-kappaB. Our lab has been studying NF-kappaB for a number of years and has published that this protein is important in KRAS signaling. But how KRAS activates NF-kappaB has not been well understood. We have found a link, ” said senior author Dr. Albert Baldwin, professor of biology at the University of North Carolina. “Our data suggest that GSK-3 alpha is really an onco-protein and that KRAS utilizes GSK-3 alpha to activate both NF-kappaB pathways, called canonical and noncanonical. This finding is important because GSK-3 alpha sits on top of the two pathways and inhibits them both, thus making it a viable therapeutic target. We are conducting further pharmacologic studies.”

Related Links:


University of North Carolina



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.